

A decorative graphic on the left side of the slide consists of a series of concentric circles centered on a vertical dashed line. The circles are light blue and increase in size from top to bottom. A horizontal line extends from the top of the dashed line to the right, connecting to the Standard Biotech logo.

# Setting Standards Empowering Research Building Shareholder Value

Q4 and 2024 Full Year Financial Results

February 26<sup>th</sup> 2025

# Legal Information

## Forward-looking statements

This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates,” “targets” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding financial outlook and business performance, including related to revenues, net loss and adjusted EBITDA, growth, margin and operating expenses; statements regarding future financial performance and expectations, operational and strategic plans, deployment of capital, cash runway and sufficiency of cash resources, potential market and growth opportunities, and future potential M&A activity; the potential to realize the expected benefits of prior and potential future acquisitions, our 2025 and 2026 financial targets, including with respect to revenue, non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, adjusted EBITDA, cash, and free cash flow; the competitive ability and position of the company, the success, cost and timing of the company’s product development, sales and marketing, and research and development activities, the company’s ability to obtain and maintain regulatory approval for its products, the sufficiency of the company’s cash, cash equivalents and short-term investments to fund operations, and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks and uncertainties related to, among other things, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring plans, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; our ability to achieve future financial targets; changes in our business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to our research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of our most recent annual report on Form 10-K filed with the SEC on March 1, 2024. We undertake no obligation to revise or update any forward-looking statements for any reason.


## Non-GAAP financial information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis. The non-GAAP financial measures included in this presentation are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this presentation.

## Trademarks

Standard BioTools, the Standard BioTools logo, Biomark, CyTOF, CyTOF XT, EP1, Helios, Hyperion, Hyperion+ and SomaScan are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation) or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners.

**Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.**



# CEO Commentary

MICHAEL EGHOLM, PHD

# Executing on Our Vision

## Building a Diversified Life Science Tools Industry Leader



**Revenue:** \$47 million in Q4 and \$175 million for the Full Year 2024<sup>1</sup>



**Clean Balance Sheet:** \$295 million in cash<sup>5</sup> provides path to adj EBITDA + expected in 2026



**Cost Synergies:** Operationalized ~\$90 million in total over the past twelve months via SBS



**Strategically Active:** 4 to 6 growth-driving transactions targeted over the next two years



**Profitability Metrics:** 22% non-GAAP OpEx<sup>1</sup> and 33% adjusted EBITDA improvements<sup>2</sup> FY24 YoY<sup>3</sup>



**2025 Outlook:** Targeting combined revenue in the range of \$165 million to \$175 million<sup>4</sup>

<sup>1</sup>Refer to Appendix for a reconciliation between GAAP and non-GAAP OpEx.

<sup>2</sup>Refer to Q4 2024 earnings press release for a reconciliation between GAAP net loss and non-GAAP adjusted EBITDA.

<sup>3</sup>Pro Forma; The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger.

<sup>4</sup>Guidance assumes a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, no expected effect from U.S. export controls and limited impact from tariffs.

<sup>5</sup>Cash and Investments.

# Leverage Standard BioTools Business System (SBS) Flywheel to Deliver Value

## APPLYING SBS TO DRIVE IMPROVEMENT

- Leverage SBS to improve quality, increase customer satisfaction and profitability
- Deliver quality improvement & cost saving opportunities to drive better customer outcomes post-acquisition

## KEY FINANCIAL & QUALITY METRICS


- 22% reduction in FY24<sup>1</sup> non-GAAP operating expenses<sup>2</sup>
- 33% improvement in adjusted EBITDA<sup>3</sup> FY 2024<sup>1</sup>
- 98% on time delivery Q4 2024 vs 78% Q4 2022
- 4+ fold reduction in complaints FY 2024 vs FY 2022

<sup>1</sup>Pro Forma; The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger.

<sup>2</sup>Refer to Appendix for a reconciliation between GAAP and non-GAAP OpEx.

<sup>3</sup>Refer to Q4 2024 earnings press release for a reconciliation between GAAP net loss and non-GAAP adjusted EBITDA.

## SBS FLYWHEEL




# Tactics: Climb the *Value* PYRAMID, Expand the *Customer* PIE

## CLIMB UP TOWARDS MARGIN


## EXPAND FOR TAM & GROWTH

- **APPLYING** M&A to add products, customers, and end-markets
- **TARGETING** consumables with higher margins at top of pyramid
- **FOCUSING** on instruments with high pull through relative to ASP
- **EXPANDING** service offerings to increase technology adoption


CURRENT (FY24) PRODUCT MIX




FUTURE PRODUCT MIX<sup>2</sup>



CURRENT END MARKETS



FUTURE END MARKETS



<sup>1</sup>Management estimate <sup>2</sup>Anticipated

\*Non-GAAP gross margin excludes amortization of developing technology, non-cash stock-based compensation, and depreciation and amortization. Refer to Appendix for a reconciliation between GAAP and non-GAAP gross margin


\*\*Includes 3% of other revenue

**STANDARD BIOTOOLS™**

# Proteomics: A Large Opportunity, Entering Transformative Era

**Proteomics TAM<sup>1</sup>**  
Large + High CAGR

**Transformative Era**  
Impacting Large Areas of Human Health



**Genomic Driven**

**Proteomic Driven**



**Limited / Targeted Populations**

*Targeted Oncology  
& Gene Variant Diseases*

**Large, Growing Populations**

*Cardiometabolic (i.e. GLP-1),  
cardiovascular, Alzheimer's, and  
immunological disease*

**Standard BioTools' DNA based SOMAmers are Positioned to Capitalize on Large Opportunity Ahead**

<sup>1</sup> Biospace 2024.


# Integration of SOMAmers with Illumina's Leading NGS Platform

## DNA based SOMAmers + Illumina NGS



**Key '24/'25 Data:**  
*UK Biobank & Leading Population Biomarker Studies<sup>1</sup>*

+




**Multiple '24 Studies:**  
*Aptamers are Only Scalable Solution on the Market Today*


+



**2000+**  
*Installed base of NovaSeq Instruments; Expected Launch 1H25*



## Transformative Opportunity



**Transformative Era for Proteomics:  
Opportunity over the next decade**


<sup>1</sup>Marett et al. Nature Medicine. 2025; Western et al. Nature Genetics. 2024; Shen et al. Cell. 2024



# Portfolio Wide Diversification


Capitalizing on Transition from Genomics to Proteomics

## FULL YEAR '24 REVENUE MIX




### SERVICES & CONSUMABLES


**SOMASCAN**  
PLASMA  
PROTEOME



**KREX**  
ANTIBODY  
PROFILING



**OMICS AS A SERVICE**  
SINGLE CELL PROTEOMICS  
SPATIAL PROTEOMICS



### INSTRUMENTS & CONSUMABLES

**CYTOF**  
SINGLE CELL  
PROTEOMICS



**HYPERION**  
SPATIAL  
PROTEOMICS



**BIOMARK**  
FLUIDICS  
WORKFLOW



# M&A Pipeline: Disciplined Criteria and Filling Funnel

## M&A FOCUS & CRITERIA

### DIVERSIFIES PRODUCT MIX & END MARKET

- High margin recurring consumables
- Diversified product mix
- Growth in pharma and new end markets

### DE-RISKED TECHNOLOGY


- Science fully understood
- Deployable product

### PATH TO COMMERCIALIZATION

- Clear unmet need & product market fit
- Rigorously validated
- Systematic Voice-of-Customer (VOC) work

### SBS SYNERGIES

- Accelerate Sales/Adoption
- Leverage global scale
- Ops and Manufacturing





# Next Inning for Standard BioTools

## Building a Diversified Life Science Tools Industry Leader

### PHASE 1: 2022 TO 2024

**Merged Two Businesses:** Turned around two technology focused cash burning situations to \$175 million in revenue with path to profitability in 2026

**Moving Up Pyramid to Higher GM Businesses:** Transitioned to 80% consumable and services mix in attractive end markets


**Leveraged SBS to Drive Business Execution:** \$110 million+ in total cost savings across two acquisitions<sup>1</sup>, improving cost and quality metrics

### PHASE 2: 2025 TO 2026

**Close 4-6 Growth Driving Acquisitions:** Emerging LST & biopharma market challenges create unique consolidation opportunity

**Shift Product Portfolio Mix Up Value Pyramid:** Continued evolution into high-margin consumables and kits through Illumina launch & focused M&A

**Deliver Profitable, Lean Enterprise with SBS:** Continuous improvement to ensure profitable growth & long-term shareholder value



# CFO Commentary

ALEX KIM

# Revenue

## Continued Focus on Diversifying Revenue Mix

Pro Forma Combined	Q4 2024	YOY	FY 2024	YOY
Consumables	\$15M	10%	\$60M	18%
Instruments	\$9M	(25%)	\$29M	(27%)
Lab Services	\$16M	(18%)	\$57M	(21%)
Field Services	\$6M	(10%)	\$25M	(2%)
Collaboration and other	\$2M	116%	\$5M	7%
<b>TOTAL</b>	<b>\$47M</b>	<b>(9%)</b>	<b>\$175M</b>	<b>(9%)</b>

Pro Forma Combined	Q4 2024	YOY	FY 2024	YOY
Proteomics (Px)	\$37M	(7%)	\$136M	(9%)
Genomics (Gx)	\$10M	(15%)	\$39M	(9%)
<b>TOTAL</b>	<b>\$47M</b>	<b>(9%)</b>	<b>\$175M</b>	<b>(9%)</b>

- Consumables growth driven by kit sales to authorized sites and Illumina early access program
- Instrument revenue declined due to continued capital spending constraints
- Services revenue impacted by smaller projects from top customers, with continued expansion of customer base

The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger. See "Unaudited Pro Forma Results" below for discussion of the pro forma financial information. Numbers may not add, and percentages may not foot due to rounding.

# Gross Margin (Non-GAAP)

## Executing Roadmap to Expanded Gross Margin Profile

Pro Forma Combined	Q4 2024	YoY	FY 2024	YoY
Non-GAAP Gross Margin \$	\$25M	(\$4M)	\$93M	(\$9M)
Non-GAAP Gross Margin %	53%	(290 bps)	53%	(10 bps)

- Q4 2024 over Q4 2023 impacted primarily due to lower volume and higher instrument replacements, partially offset by incremental improvements from SBS.

**Non-GAAP gross margin excludes amortization of developed technology, non-cash stock-based compensation, and depreciation and amortization. Refer to Appendix for a reconciliation between GAAP and non-GAAP gross margin.**

The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger. Numbers may not add, and percentages may not foot due to rounding.

# Operating Expenses (OpEX) (Non-GAAP)

Non-GAAP OpEx Reduction Showing up in Run Rate

Pro Forma Combined	Q4 2024	YoY	YoY %	FY 2024	YoY	YoY %
R&D	\$12M	(\$4M)	(24%)	\$54M	(\$5M)	(9%)
SG&A	\$31M	(\$10M)	(24%)	\$126M	(\$47M)	(27%)
<b>Total</b>	<b>\$43M</b>	<b>(\$14M)</b>	<b>(24%)</b>	<b>\$180M</b>	<b>(\$52M)</b>	<b>(22%)</b>

- **24%** and **\$14M** reduction in Q4 2024 pro forma combined non-GAAP OpEx over Q4 2023
- Ahead of plan on synergies with \$80M merger cost synergies operationalized in 2024

**Non-GAAP OpEx excludes stock-based compensation, depreciation and amortization. Refer to Appendix for a reconciliation between GAAP and non-GAAP OpEx.**

The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger. Numbers may not add, and percentages may not foot due to rounding.

# Adjusted EBITDA (Non-GAAP)

Maintain Vigilance and Focus on Bottom Line

Pro Forma Combined	Q4 2024	YoY	FY 2024	YoY
Operating Loss \$	(\$33M)	<b>\$32M</b>	(\$180M)	<b>\$38M</b>
Net Loss \$	(\$34M)	<b>\$21M</b>	(\$169M)	<b>(\$4M)</b>
Adjusted EBITDA \$	(\$18M)	<b>\$10M</b>	(\$87M)	<b>\$43M</b>

- **34%** and **\$10M** improvement in Q4 2024 pro forma combined Adjusted EBITDA over Q4 2023

**Adjusted EBITDA excludes purchase accounting items, restructuring charges, transaction and integration expenses, stock-based compensation, gain/loss on disposal of property and equipment, and other non-operating expenses. Refer to Q4 2024 earnings press release for a reconciliation between GAAP net loss and non-GAAP adjusted EBITDA.**

The selected 2024 unaudited pro forma financial information combines the Company's financial results for the three and twelve month periods ended December 31, 2024, and the historical results of SomaLogic for the five-day period ended on January 5, 2024, the closing date of the Merger. Numbers may not add, and percentages may not foot due to rounding.



# Cash

## Runway to Execute Growth Strategy

Cash & equivalents, restricted cash and short-term investments

AT 12/31/2024


\$295.0M

	Q4 2024	Q4 2023
Adjusted Cash Burn	\$10.1M	\$9.2M
Debt Retirement	55.0M	-
Share repurchases	-	0.2M
Transaction and Integration-Related	3.5M	4.9M
Restructuring-Related	1.1M	2.4M
Capex	2.9M	1.3M
Total Pro Forma Combined Cash Use	\$72.6M	\$18.0M

Clean balance sheet to support continued growth initiatives


Planned reduction in operating burn through long-term revenue growth, gross margin expansion and OpEx synergies

Cash runway expected to fund business to adjusted EBITDA positive



# Closing Remarks

MICHAEL EGHOLM, PHD



## Appendix: Financials

# Capitalization Table

<i>(in millions, except per share data)</i>	<b>Issued and Outstanding<sup>(a)</sup></b>	<b>Fully Diluted</b>
Common Shares	378	378
Restricted Stock Units	-	13
Warrants <sup>(b)</sup>	-	12
Stock Options <sup>(c)</sup>	-	39
<b>Total Shares</b>	<b>378</b>	<b>442</b>
<b>Market Capitalization <sup>(d)</sup></b>	<b>\$662</b>	
Cash and short-term investments at December 31, 2024	\$ 295	
<b>Enterprise Value<sup>(e)</sup></b>	<b>\$ 367</b>	

(a) Capitalization table is reflective of common shares and equivalents reported as of December 31, 2024.

(b) Warrants outstanding as of December 31, 2024 were 10.5 million, convertible to shares of Standard BioTools common stock at an exchange ratio of 1.11. Warrants are reflected on a fully dilutive basis.

(c) Outstanding options have a weighted average exercise price of \$4.26.

(d) Based on \$1.75 closing price of common stock on December 31, 2024.

(e) Reflects market capitalization less cash, cash equivalents, restricted cash, and short-term investments as of December 31, 2024.

# Non-GAAP Reconciliation

## Gross Margin

	As Reported		Pro Forma	
<i>(in millions)</i>	Q4 2024	Q4 2023	Q4 2024	Q4 2023
<b>GAAP Gross Profit</b>	<b>\$21.9</b>	<b>\$13.4</b>	<b>\$21.9</b>	<b>\$24.0</b>
Add: Amortization of Acquired Intangible Assets	0.6	2.8	0.6	3.4
Add: Depreciation and Amortization in COGS	1.5	0.5	1.5	0.9
Add: Stock-Based Comp in COGS	0.5	0.2	0.5	0.2
Add: Cost of Sales Adjustment	0.0	0.0	0.0	0.0
<b>Non-GAAP Gross Profit</b>	<b>\$24.5</b>	<b>\$16.8</b>	<b>\$24.5</b>	<b>\$28.5</b>
<b>GAAP Gross Margin</b>	<b>46.9%</b>	<b>47.4%</b>	<b>46.9%</b>	<b>46.7%</b>
Add: Amortization of Acquired Intangible Assets	1.4	9.9	1.4	6.5
Add: Depreciation and Amortization in COGS	3.2	1.7	3.2	1.8
Add: Stock-Based Comp in COGS	1.0	0.6	1.0	0.4
Add: Cost of Sales Adjustment	0.0	0.0	0.0	0.0
<b>Non-GAAP Gross Margin</b>	<b>52.5%</b>	<b>59.6%</b>	<b>52.5%</b>	<b>55.4%</b>

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.

# Non-GAAP Reconciliation - YTD

## Gross Margin

(in millions)	As Reported		Pro Forma	
	Q4 YTD 2024	Q4 YTD 2023	Q4 YTD 2024	Q4 YTD 2023
<b>GAAP Gross Profit</b>	<b>\$84.3</b>	<b>\$50.5</b>	<b>\$82.8</b>	<b>\$85.9</b>
Add: Amortization of Acquired Intangible Assets	3.7	11.2	3.7	13.4
Add: Depreciation and Amortization in COGS	4.9	1.5	4.9	3.1
Add: Stock-Based Comp in COGS	1.4	0.8	1.4	1.0
Add: Cost of Sales Adjustment	(1.8)	0.0	0.0	(1.3)
<b>Non-GAAP Gross Profit</b>	<b>\$92.4</b>	<b>\$63.9</b>	<b>\$92.8</b>	<b>\$102.1</b>
<b>GAAP Gross Margin</b>	<b>48.3%</b>	<b>47.4%</b>	<b>47.3%</b>	<b>44.7%</b>
Add: Amortization of Acquired Intangible Assets	2.1	10.5	2.1	7.0
Add: Depreciation and Amortization in COGS	2.8	1.4	2.8	1.6
Add: Stock-Based Comp in COGS	0.8	0.8	0.8	0.5
Add: Cost of Sales Adjustment	(1.0)	0.0	0.0	(0.7)
<b>Non-GAAP Gross Margin</b>	<b>53.0%</b>	<b>60.1%</b>	<b>53.0%</b>	<b>53.1%</b>

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.

# Non-GAAP Reconciliation

## Operating Expenses

	As Reported		Pro Forma	
<i>(in millions)</i>	Q4 2024	Q4 2023	Q4 2024	Q4 2023
<b>GAAP R&amp;D</b>	<b>\$14.1</b>	<b>\$6.9</b>	<b>\$14.1</b>	<b>\$17.0</b>
Less: Stock-Based Comp in R&D	1.3	0.4	1.3	0.8
Less: Depreciation and Amortization in R&D	0.9	0.1	0.9	0.5
<b>Non-GAAP R&amp;D</b>	<b>\$11.8</b>	<b>\$6.4</b>	<b>\$11.8</b>	<b>\$15.7</b>
<b>GAAP SG&amp;A</b>	<b>\$37.6</b>	<b>\$21.4</b>	<b>\$37.6</b>	<b>\$46.3</b>
Less: Stock-Based Comp in SG&A	5.6	2.9	5.6	4.0
Less: Amortization of Acquired Intangible Assets	0.2	0.0	0.2	0.2
Less: Depreciation and Amortization in SG&A	0.8	0.5	0.8	1.3
Less: (Gain)/Loss on Disposal of PP&E	(0.1)	0.0	(0.1)	0.0
<b>Non-GAAP SG&amp;A</b>	<b>\$31.1</b>	<b>\$18.0</b>	<b>\$31.1</b>	<b>\$40.8</b>

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.

# Non-GAAP Reconciliation - YTD

## Operating Expenses

	As Reported		Pro Forma	
<i>(in millions)</i>	Q4 YTD 2024	Q4 YTD 2023	Q4 YTD 2024	Q4 YTD 2023
<b>GAAP R&amp;D</b>	<b>\$62.4</b>	<b>\$25.9</b>	<b>\$63.1</b>	<b>\$64.5</b>
Less: Stock-Based Comp in R&D	5.8	1.7	5.8	3.3
Less: Depreciation and Amortization in R&D	3.5	0.5	3.5	2.1
<b>Non-GAAP R&amp;D</b>	<b>\$53.1</b>	<b>\$23.8</b>	<b>\$53.8</b>	<b>\$59.1</b>
<b>GAAP SG&amp;A</b>	<b>\$156.6</b>	<b>\$87.5</b>	<b>\$149.1</b>	<b>\$201.2</b>
Less: Stock-Based Comp in SG&A	24.5	10.6	17.7	21.8
Less: Amortization of Acquired Intangible Assets	0.7	0.0	0.7	0.6
Less: Depreciation and Amortization in SG&A	4.1	2.0	4.1	5.5
Less: (Gain)/Loss on Disposal of PP&E	0.3	0.1	0.3	0.1
<b>Non-GAAP SG&amp;A</b>	<b>\$127.0</b>	<b>\$74.8</b>	<b>\$126.4</b>	<b>\$173.1</b>

Figures are derived from Condensed Consolidated Statements of Operations as reported in the Company's Reports on Form 10-Q for the relevant periods. | Numbers may not add, and percentages may not foot due to rounding.